Q-omics provides the consensus-scored CCDC77 profile across patient tissues and cancer cell-line models. CCDC77 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CCDC77 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CCDC77 protein abundance shows 22,707 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, HNSC, and LUAD as cancer lineages where CCDC77 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC77 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC77 survival associations across molecular data types. CCDC77 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC77 RNA expression–survival associations across cancer types. High CCDC77 expression shows unfavorable associations in ACC, LIHC, MESO, LGG, KIRC and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CCDC77 RNA expression.
This table summarizes CCDC77 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC77. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC77 shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, STAD and COAD. The HNSC box plot shows higher CCDC77 RNA expression in tumor versus normal tissue (log2 FC = +1.073, t-test p < 0.001).
This table shows molecular features associated with CCDC77 in patient tissues and cancer cell lines. In patient samples, CCDC77 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC77 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
